search
Back to results

Integrated Care Pathway for Youth Depression (CARIBOU)

Primary Purpose

ICP1, Depression, Adolescent Behavior

Status
Unknown status
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Integrated Care Pathway
Treatment As Usual
Sponsored by
Centre for Addiction and Mental Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for ICP1

Eligibility Criteria

14 Years - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Psychiatrist's impression is that depression is a primary psychiatric. concern
  • 14-18 years old.
  • DSM-5 criteria for Major Depressive Disorder or Persistent Depressive Disorder as per the Diagnostic Interview for Affective Symptoms for Children (DIAS-C19).
  • Speak, read and write English at a grade 6 level.

Exclusion Criteria:

  • Threshold psychotic symptoms.
  • Bipolar disorder.
  • Moderate-to-severe substance use disorder.
  • Autistic spectrum disorder or intellectual disability.
  • Eating disorder.
  • Suicide-related behaviours requiring acute intervention.

Sites / Locations

  • Sunnybrook Health Sciences Centre
  • The Center for Addiction and Mental HealthRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Integrate Care Pathway

Treatment As Usual

Arm Description

The intervention is an Integrated Care Pathway with 3 key components. Clinical Practice Guidelines (CPG) recommendations: The initial template of the treatment protocol was based on the NICE CPGs for Depression in Children and Young People. Provider engagement: The clinicians at CAMH reviewed the template and collaboratively developed a flow chart defining the treatment protocol. Measurement-based care: Feedback measures are taken every four weeks and the results are provided to the clinician, patient and family to inform treatment decisions. The feedback measures are the Mood and Feelings Questionnaire, the Columbia Impairment Scale (CIS) and the General Functioning Domain of the McMaster Family Assessment Device (MFAD).

Treatment As Usual : Participants at SHSC will receive treatment at could include a psychiatric evaluation, possible medication management and various types of psychotherapy, including cognitive-behavioural therapy, interpersonal psychotherapy, psychodynamic psychotherapy and family therapy. There is no structured protocol and no systematic Measurement Based Care. A research assistant will record the interventions received in either group via chart review.

Outcomes

Primary Outcome Measures

Change in Childhood Depression Rating Scale-Revised scores
The CDRS-R is a 17-item measure rated by an evaluator after a semi-structured interview with the adolescent relating to symptoms of depression over the past 2 weeks. Scores range from 0 to 100 with a score of over 55 interpreted as a moderate to severe rating. Lower values represent a better outcome.

Secondary Outcome Measures

Change in WHO Disability Assessment Schedule 2.0 for Children And Youth
Change in function as reported by participant The sum of scores of the items across all domains constitutes a statistic that is sufficient to describe the degree of functional limitations. Lower values represent a decrease in their subjective depression rating over the previous 2 weeks.
Change in Childhood Behaviour Checklist
Change in overall psychopathology as reported by caregiver.Total scores may be computed for Social Competence, Behavior Problems, Internalizing Problems, and Externalizing Problems, plus scores for each of the 8 syndrome scales. Raw scores are converted to age-standardized scores (T-Scores). T scores less than 67 are considered in the normal range, T scores ranging from 67-70 are considered to be borderline clinical, and T scores above 70 are in the clinical range.

Full Information

First Posted
February 2, 2018
Last Updated
August 8, 2018
Sponsor
Centre for Addiction and Mental Health
Collaborators
Sunnybrook Health Sciences Centre
search

1. Study Identification

Unique Protocol Identification Number
NCT03428555
Brief Title
Integrated Care Pathway for Youth Depression
Acronym
CARIBOU
Official Title
Is an Integrated Care Pathway for Adolescents With Depression More Effective Than Treatment as Usual? A Controlled Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2018
Overall Recruitment Status
Unknown status
Study Start Date
March 29, 2018 (Actual)
Primary Completion Date
August 29, 2019 (Anticipated)
Study Completion Date
February 21, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Centre for Addiction and Mental Health
Collaborators
Sunnybrook Health Sciences Centre

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
Major Depressive Disorder in adolescence is prevalent and debilitating. Our group aims to improve treatment response through the use of an Integrated Care Pathway (ICP) based on a high quality Clinical Practice Guideline and measurement-based care (MBC; where periodic symptom scale scores are used to make treatment decisions). We propose a controlled clinical trial comparing ICP to treatment-as-usual (TAU) across two sites.
Detailed Description
Background: There is a gap between what is known from the evidence about the treatment of adolescent depression and what is practiced. Moreover, while there is evidence that measurement-based care can improve outcomes for adults with various mental health conditions, there is limited information on this framework in adolescent depression. Objective: Our study aims to enhance the implementation of evidence-based care (using the NICE Clinical Practice Guidelines as a template) combined wtih measurement-based care through the use of an Integrated Care Pathway (ICP) in adolescents with depression. Hypothesis: As this is a pilot study, our hypotheses centre around feasibility. We hypothesize that: (1) we will recruit at least 30 participants to the ICP treatment arm and 30 participants at the "treatment-as-usual" arm at a different site (2) that baseline measures will be fully completed by 95% of adolescents recruited, (3) that baseline measures will take 2 hours to complete for adolescents and 1 hour to complete for caregivers, (4) that a mean of 90% of the key aspects of the treatment protocol are followed in the ICP group (5) that 80% of participants recruited will complete measures at the end of the 20-week interval and that (6) 90% of the youth, caregivers and clinicians who partake int eh study will attend a focus group to provide qualitative feedback on their experience. Design: This is a non-randomized controlled clinical trial. Randomizing at the individual level is not possible - the intervention is implemented at the clinic level; so the effect of the intervention on one youth within a clinic would influence the care of other youth at the clinic. Sampling: Participants are recruited from psychiatric clinics at 2 sites. Each site will recruit to their respective treatment arm.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
ICP1, Depression, Adolescent Behavior

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Intervention Arm (n=30 over 17 months at, CAMH): The intervention is an integrated care pathway and Comparison Arm- Treatment As Usual (n=30 over 17 months at SHSC):
Masking
None (Open Label)
Masking Description
Participants are not blinded.
Allocation
Non-Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Integrate Care Pathway
Arm Type
Experimental
Arm Description
The intervention is an Integrated Care Pathway with 3 key components. Clinical Practice Guidelines (CPG) recommendations: The initial template of the treatment protocol was based on the NICE CPGs for Depression in Children and Young People. Provider engagement: The clinicians at CAMH reviewed the template and collaboratively developed a flow chart defining the treatment protocol. Measurement-based care: Feedback measures are taken every four weeks and the results are provided to the clinician, patient and family to inform treatment decisions. The feedback measures are the Mood and Feelings Questionnaire, the Columbia Impairment Scale (CIS) and the General Functioning Domain of the McMaster Family Assessment Device (MFAD).
Arm Title
Treatment As Usual
Arm Type
Active Comparator
Arm Description
Treatment As Usual : Participants at SHSC will receive treatment at could include a psychiatric evaluation, possible medication management and various types of psychotherapy, including cognitive-behavioural therapy, interpersonal psychotherapy, psychodynamic psychotherapy and family therapy. There is no structured protocol and no systematic Measurement Based Care. A research assistant will record the interventions received in either group via chart review.
Intervention Type
Behavioral
Intervention Name(s)
Integrated Care Pathway
Intervention Description
The intervention is a integrated care pathway based on the NICE Clinical Practice Guidelines and measurement-based care in the form of a flow chart. Each decision point on the pathway is guided by results of self-report measures for depression (the Mood and Feelings Questionnaire), functional impairment (Columbia Impairment Scales) and family functioning (the McMaster Family Assessment Device). The results of these scales and protocol recommendations are fed back to the patients, families and clinicians in order to make further treatment decisions
Intervention Type
Behavioral
Intervention Name(s)
Treatment As Usual
Intervention Description
Treatment As Usual represents what clinicians would typically do when presented with an adolescent with depression. There is no algorithm provided to guide clinical decision-making and no systematic measurement-based care.
Primary Outcome Measure Information:
Title
Change in Childhood Depression Rating Scale-Revised scores
Description
The CDRS-R is a 17-item measure rated by an evaluator after a semi-structured interview with the adolescent relating to symptoms of depression over the past 2 weeks. Scores range from 0 to 100 with a score of over 55 interpreted as a moderate to severe rating. Lower values represent a better outcome.
Time Frame
20 weeks
Secondary Outcome Measure Information:
Title
Change in WHO Disability Assessment Schedule 2.0 for Children And Youth
Description
Change in function as reported by participant The sum of scores of the items across all domains constitutes a statistic that is sufficient to describe the degree of functional limitations. Lower values represent a decrease in their subjective depression rating over the previous 2 weeks.
Time Frame
20 weeks
Title
Change in Childhood Behaviour Checklist
Description
Change in overall psychopathology as reported by caregiver.Total scores may be computed for Social Competence, Behavior Problems, Internalizing Problems, and Externalizing Problems, plus scores for each of the 8 syndrome scales. Raw scores are converted to age-standardized scores (T-Scores). T scores less than 67 are considered in the normal range, T scores ranging from 67-70 are considered to be borderline clinical, and T scores above 70 are in the clinical range.
Time Frame
20 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
14 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Psychiatrist's impression is that depression is a primary psychiatric. concern 14-18 years old. DSM-5 criteria for Major Depressive Disorder or Persistent Depressive Disorder as per the Diagnostic Interview for Affective Symptoms for Children (DIAS-C19). Speak, read and write English at a grade 6 level. Exclusion Criteria: Threshold psychotic symptoms. Bipolar disorder. Moderate-to-severe substance use disorder. Autistic spectrum disorder or intellectual disability. Eating disorder. Suicide-related behaviours requiring acute intervention.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Darren B Courtney, MD
Phone
416-535-8501
Ext
30539
Email
darren.courtney@camh.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Michelle Li, BA
Phone
416-535-8501
Ext
39144
Email
michelle.li1@camh.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Szatmari, MD
Organizational Affiliation
The Center for Addiction and Mental Health
Official's Role
Study Director
Facility Information:
Facility Name
Sunnybrook Health Sciences Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M4Y 3M5
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Amy Cheung, MD
Phone
4164804073
Email
amy.cheung@sunnybrook.ca
First Name & Middle Initial & Last Name & Degree
Michelle Li, BA
Phone
4164804073
Email
michelle.li@sunnybrook.ca
Facility Name
The Center for Addiction and Mental Health
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M6J 1H4
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Darren B Courtney, MD
Phone
416-535-8501
Ext
30539
Email
darren.courtney@camh.ca
First Name & Middle Initial & Last Name & Degree
Susan Dickens, MA
Phone
416-535-8501
Email
susan.dickens@camh.ca

12. IPD Sharing Statement

Learn more about this trial

Integrated Care Pathway for Youth Depression

We'll reach out to this number within 24 hrs